Last Updated: 2/19
Share or print this information to talk to your doctor about this trial.
The primary purpose of this open-label, Phase 2 proof of concept study is to evaluate the efficacy of 12 months of oral ACH-0144471 in participants with C3G or IC-MPGN based on renal biopsy results and the number and percentage of participants with an improvement relative to baseline in clinical manifestation(s) of C3G (proteinuria and reduced estimated glomerular filtration rate [eGFR]).
17 to 65
NOTE: Additional inclusion/exclusion criteria will apply, per protocol.
University of Alabama
Birmingham, AL 35294
Stanford, CA 94305
Yale University School of Medicine
New Haven, CT 06511
University of Cincinnati
Cincinnati, OH 45221
Ohio State University
Columbus, OH 43210
University of Pennsylvania
Philadelphia, PA 19104
Royal Brisbane and Women’s Hospital
The Royal Melbourne Hospital
Sydney, New South Wales
IRCCS-Instituto di Ricerche Farmacologiche Mario Negri
Amalia Children’s Hospital
Radboud University Nijmegen Medical Centre
Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contact information provided below.
Clinical Operations | 203-752-5566
View complete study information on ClinicalTrials.gov
Thank you for visiting WeC3GTM
You are now leaving the WeC3G.com website and being directed to a third-party website. Achillion Pharmaceuticals, Inc. is not responsible for the content of the site you are about to visit.
Would you like to continue?
Continued use of this site indicates you have accepted this policy.